<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04763200</url>
  </required_header>
  <id_info>
    <org_study_id>VV-TMF-18508</org_study_id>
    <nct_id>NCT04763200</nct_id>
  </id_info>
  <brief_title>Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function</brief_title>
  <acronym>PROTECT IV</acronym>
  <official_title>Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function: The PROTECT IV Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abiomed Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abiomed Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device&#xD;
      during high-risk PCI in patients with reduced left-sided heart function will result in an&#xD;
      improvement in symptoms, heart function and health after a heart procedure compared to the&#xD;
      current standard of care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To demonstrate that in high-risk patients with complex CAD and reduced left ventricular&#xD;
      function undergoing PCI, PCI with Impella Mechanical Circulatory Support (MCS) is superior to&#xD;
      PCI without Impella MCS in reducing the composite rate of all-cause death, stroke, MI or&#xD;
      hospitalization for cardiovascular causes at 3-year follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2021</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, multicenter, randomized, parallel-controlled, open-label two-arm trial with an adaptive design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The composite of all-cause death, stroke, MI or hospitalization for cardiovascular (CV) causes.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death or NYHA Class III or IV</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in KCCQ</measure>
    <time_frame>Baseline to 6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6MWD</measure>
    <time_frame>6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All CV hospitalizations</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of CV death, stroke, MI or hospitalization for cardiovascular cause</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CV death or HF hospitalizations</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in LVEF based on ANCOVA regression with inclusion of baseline LVEF measurement as a covariate</measure>
    <time_frame>Baseline to 6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete ischemic revascularization evaluated using Pearson's chi-square test for proportion difference</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1252</enrollment>
  <condition>Left Ventricular Dysfunction</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Impella Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Impella CP® or Impella 2.5 placement prior to high-risk PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to the Control group will be treated per standard of care PCI with or without an intra-aortic balloon pump (IABP).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®</intervention_name>
    <description>Impella CP / Impella CP with SmartAssist will be used in most patients randomized to the Impella arm. Impella 2.5 may be used in patients with small body size (BMI &lt;20 kg/m2 or body weight &lt;60 kg) or if the iliofemoral vasculature is able to accommodate the smaller Impella 2.5 device but not the Impella CP device.</description>
    <arm_group_label>Impella Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IABP Intra-aortic balloon pump</intervention_name>
    <description>IABP uses counterpulsation to provide 0.2L/min coronary flow</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years and ≤90 years&#xD;
&#xD;
          2. Clinical presentation and baseline left ventricular function are as follows: Either 2A&#xD;
             or 2B must be present&#xD;
&#xD;
             A. Subject has CCS or NSTEMI with an LVEF ≤40% NOTE: The LVEF must be quantitatively&#xD;
             measured as ≤40% by echo within 30 days assuming no change in clinical condition. If&#xD;
             multiple echos have been performed within 30-days, the most recent test must be used&#xD;
             to qualify the patient. NOTE: Subject qualifies if the quantitative site read LVEF is&#xD;
             ≤30%; if the quantitative site read is &gt;30% - ≤40% the Echo Core Lab must confirm the&#xD;
             LVEF is ≤40% before subject enrollment (Core Lab will provide &lt;48-hour turnaround).&#xD;
             Similarly, if the site read is qualitative only (i.e., only provides broad ranges&#xD;
             without detailed LVEF quantification), the Echo Core Lab must confirm the LVEF is ≤40%&#xD;
             before subject enrollment.&#xD;
&#xD;
             OR&#xD;
&#xD;
             B. Subject has STEMI ≥24 hours and &lt;30 days after symptom onset with an LVEF ≤30%&#xD;
             NOTE: In patients qualifying with recent STEMI, the LVEF must be demonstrated to be&#xD;
             ≤30% by quantitative echocardiography after the primary PCI procedure (if performed)&#xD;
             and within 72-hours prior to the planned randomization. If primary PCI was not&#xD;
             performed, the qualifying echocardiogram will be the one taken during the index&#xD;
             hospitalization closest to the index procedure. If the site read is qualitative only&#xD;
             (i.e., only provides broad ranges without detailed LVEF quantification), the Echo Core&#xD;
             Lab must confirm the LVEF is ≤30% before subject enrollment.&#xD;
&#xD;
          3. Local heart team (interventional cardiologist and cardiac surgeon) has determined that&#xD;
             PCI is indicated and is the most appropriate management for the patient&#xD;
&#xD;
          4. Complex PCI will be performed: Either 4A or 4B must be met&#xD;
&#xD;
             A. One of the following must be present:&#xD;
&#xD;
             i. Triple vessel disease is present (visually-assessed angiographic DS ≥80% [or ≥40%&#xD;
             if non-invasive evidence of ischemia on a localizing stress test or invasive evidence&#xD;
             of ischemia (FFR ≤0.80 or iFR ≤0.89)] is present in all 3 epicardial coronary artery&#xD;
             distributions in a main vessel or branch with visually-assessed reference vessel&#xD;
             diameter ≥2.5 mm) with PCI planned in ≥2 of these vessels in the proximal or mid LAD,&#xD;
             proximal or mid-LCX or proximal, mid- or distal RCA [i.e., not a branch vessel])&#xD;
&#xD;
             OR&#xD;
&#xD;
             ii. Left main distal bifurcation or trifurcation disease (visually-assessed DS ≥50%&#xD;
             [or DS ≥30% if non-invasive evidence of ischemia in both the anterior and&#xD;
             posterolateral distributions or left main IVUS MLA ≤6.0 mm2 or FFR ≤0.80 or iFR ≤0.89]&#xD;
             is present) with planned intervention of the left main plus at least 2 branch vessels&#xD;
             (i.e., the ostial LAD, ostial LCX or ostial ramus)&#xD;
&#xD;
             OR&#xD;
&#xD;
             iii. Left main equivalent disease with both ostial LAD and ostial LCX having&#xD;
             visually-assessed angiographic DS ≥80% [or ≥40% if non-invasive evidence of ischemia&#xD;
             on a localizing stress test or invasive evidence of ischemia (FFR ≤0.80 or iFR ≤0.89]&#xD;
             and requiring intervention in both branches&#xD;
&#xD;
             OR&#xD;
&#xD;
             iv. Intervention of the last remaining vessel (native coronary artery or bypass graft)&#xD;
&#xD;
             OR&#xD;
&#xD;
             B. Multivessel disease is present (visually-assessed angiographic DS ≥80% [or ≥40% if&#xD;
             non-invasive or invasive evidence of ischemia is present] in ≥2 of the 3 epicardial&#xD;
             coronary artery distributions in a main vessel or branch with visually-assessed&#xD;
             reference vessel diameter ≥2.5 mm) and PCI is planned of at least 2 separate complex&#xD;
             lesions in main vessels or branch vessels each having one or more of the following&#xD;
             characteristics:&#xD;
&#xD;
             i. Long lesion (≥28 mm visually assessed) requiring ≥30 mm stent length (single or&#xD;
             multiple)&#xD;
&#xD;
             ii. Severe angiographic calcification (see Protocol definition) or requiring&#xD;
             atheroablation&#xD;
&#xD;
             iii. Any left main morphology not in Criterion A requiring intervention (e.g.,&#xD;
             isolated ostial or mid-shaft left main lesion or distal left main bifurcation lesion&#xD;
             with a planned single provisional stent technique)&#xD;
&#xD;
             iv. Non-left main bifurcation lesion requiring intervention in both the main branch&#xD;
             and side branch&#xD;
&#xD;
             v. CTO (TIMI 0 Flow)&#xD;
&#xD;
             vi. Giant thrombus (length ≥3x vessel diameter)&#xD;
&#xD;
             vii. SVG (other than focal (&lt;5 mm) disease of the proximal or distal anastomosis or&#xD;
             in-stent restenosis)&#xD;
&#xD;
             NOTES:&#xD;
&#xD;
               1. The multiple lesions can be in the same vessel if separated by ≥10 mm - however,&#xD;
                  each separate lesion has to have one or more of the above characteristics&#xD;
&#xD;
               2. PCI may be performed on additional non-qualifying lesions (i.e., without 1 or&#xD;
                  more of the above high-risk characteristics) as long as there are at least two&#xD;
                  lesions also undergoing PCI with each having 1 or more of the above&#xD;
                  characteristics)&#xD;
&#xD;
               3. There are 2 exceptions to the rule that each separate lesion must have one or&#xD;
                  more of the above characteristics (as in Inclusion Criterion 4B above): The&#xD;
                  subject may qualify if undergoing complex PCI of a single lesion that has 2 or&#xD;
                  more of the above complex characteristics (as in Inclusion Criterion 4B above) if&#xD;
                  also:&#xD;
&#xD;
             i. There is a CTO of a proximal or mid-LAD, proximal or mid-LCX or proximal, mid- or&#xD;
             distal RCA (i.e., not a branch vessel) that will not be treated&#xD;
&#xD;
             OR&#xD;
&#xD;
             ii. The subject qualifies with recent STEMI with an LVEF ≤30% and the complex PCI is&#xD;
             planned in a non-infarct vessel (i.e., a complex PCI in the infarct vessel does not&#xD;
             qualify)&#xD;
&#xD;
          5. Subject or legal guardian provides informed, written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects must not meet ANY of the following Exclusion Criteria to participate in the Trial:&#xD;
&#xD;
          1. STEMI ≤24 hours from the onset of ischemic symptoms or at any time if mechanical&#xD;
             complications of transmural infarction are present (e.g., VSD, papillary muscle&#xD;
             rupture, etc.)&#xD;
&#xD;
          2. Cardiogenic shock (SBP &lt;80 mmHg for ≥30 mins and not responsive to intravenous fluids&#xD;
             or requiring pressors or mechanical circulatory support, including IABP)&#xD;
&#xD;
          3. Subject is presently or recently intubated for the current admission (NOTE: recently&#xD;
             intubated patients must be extubated for &gt;24 hours with full neurologic recovery)&#xD;
&#xD;
          4. Cardiorespiratory arrest related to the current admission unless subject is extubated&#xD;
             for &gt;24 hours with full neurologic recovery and hemodynamically stable&#xD;
&#xD;
          5. Any contraindication or inability to Impella placement in both the left and right&#xD;
             common femoral artery based on clinical or imaging findings, including iliofemoral&#xD;
             artery diameter &lt;5 mm, tortuous vascular anatomy or severe bilateral peripheral&#xD;
             vascular disease of the iliac or femoral arteries that can't be adequately treated&#xD;
             (e.g., with intravascular lithotripsy)&#xD;
&#xD;
             NOTES:&#xD;
&#xD;
               1. Computed tomography (CT) or contrast angiography to assess the aorta and&#xD;
                  iliofemoral vasculature to ensure Impella compatibility must be performed within&#xD;
                  14 days of the planned randomization. Absent a CT, angiography of the potential&#xD;
                  Impella access vessel(s) may be performed in the Cath Lab before the planned&#xD;
                  enrollment after which the subject may be randomized if he/she still qualifies&#xD;
&#xD;
               2. If iliofemoral peripheral vascular disease is present precluding Impella use that&#xD;
                  can be adequately treated with angioplasty, atherectomy or lithotripsy (without a&#xD;
                  stent), the subject can be enrolled if such treatment is undertaken and is&#xD;
                  successful and uncomplicated - randomization must not be performed until such&#xD;
                  successful and uncomplicated treatment&#xD;
&#xD;
          6. Iliofemoral stents placed within 6 months of enrollment with planned vascular access&#xD;
             through these vascular segments&#xD;
&#xD;
          7. Vascular access for Impella is required in any location other than the left or right&#xD;
             common femoral artery (i.e., axillary access, transcaval access, etc., for Impella&#xD;
             access are not permitted)&#xD;
&#xD;
          8. Known left ventricular thrombus&#xD;
&#xD;
          9. Incessant ventricular arrhythmias that would likely preclude stable Impella&#xD;
             positioning&#xD;
&#xD;
         10. Severe aortic stenosis or severe aortic insufficiency&#xD;
&#xD;
         11. Prior mechanical valve or self-expanding TAVR (NOTE: prior bioprosthetic surgical&#xD;
             valve or balloon expandable TAVR implanted &gt;24 hours pre-procedure is acceptable)&#xD;
&#xD;
         12. Known severe pulmonary hypertension (right ventricular systolic pressure (RVSP) on&#xD;
             echo or pulmonary artery systolic pressure (PASP) on right heart catheterization) &gt;70&#xD;
             mm Hg unless active vasodilator therapy in the Cath Lab is able to reduce the&#xD;
             pulmonary vascular resistance (PVR) to &lt;3 Wood Units or between 3 and 4.5 Wood Units&#xD;
             with v-wave less than twice the mean of the pulmonary capillary wedge pressure&#xD;
&#xD;
         13. Moderate or severe RV dysfunction defined as TAPSE &lt;12 mm or RVFAC ≤30% as assessed on&#xD;
             baseline TTE (NOTE: these measures may be quantified at the site; if the site&#xD;
             determines qualitatively that some degree of RV dysfunction is present or the subject&#xD;
             has signs or symptoms of RV dysfunction but the site is unable to quantitate RV&#xD;
             function, the echo must be submitted for Core Laboratory assessment prior to subject&#xD;
             enrollment)&#xD;
&#xD;
         14. Platelet count &lt;75,000 cells/mm3, bleeding diathesis, coagulopathy or unwilling to&#xD;
             receive blood transfusions&#xD;
&#xD;
         15. On dialysis&#xD;
&#xD;
         16. Prior stroke with any permanent neurologic deficit or any prior intracranial&#xD;
             hemorrhage or any prior subdural hematoma or known intracranial pathology&#xD;
             pre-disposing to intracranial bleeding, such as an arteriovenous malformation or mass&#xD;
&#xD;
         17. Taking a chronic oral anticoagulant that cannot be safely discontinued for at least&#xD;
             72-hours before and 72-hours after the index procedure&#xD;
&#xD;
         18. Plan for any surgery within 6 months necessitating discontinuing antiplatelet agents&#xD;
&#xD;
         19. Pregnant or child-bearing potential unless negative pregnancy test within 1 week&#xD;
&#xD;
         20. Participation in the active treatment or follow-up phase of another clinical study of&#xD;
             an investigational drug or device that has not reached its primary endpoint&#xD;
&#xD;
         21. Any medical or psychiatric condition such as dementia, alcoholism or substance abuse&#xD;
             which may preclude informed consent or interfere with any of the study procedures,&#xD;
             including follow-up visits&#xD;
&#xD;
         22. Any non-cardiac condition with life expectancy &lt;3 years (e.g., cirrhosis, oxygen or&#xD;
             oral steroid dependent COPD, cancer not in remission, etc.)&#xD;
&#xD;
         23. Subject is currently hospitalized for definite or suspected COVID-19&#xD;
&#xD;
         24. Subject has previously been symptomatic with or hospitalized for COVID-19 unless&#xD;
             he/she has been discharged (if hospitalized) and asymptomatic for ≥8 weeks and has&#xD;
             returned to his/her prior baseline (pre-COVID) clinical condition&#xD;
&#xD;
         25. Subject is asymptomatic (never ill) and COVID-19 PCR/antigen or antibody test is&#xD;
             positive within the prior 4 weeks unless subject remains asymptomatic for ≥4 weeks&#xD;
             after the last positive test&#xD;
&#xD;
         26. Subject belongs to a vulnerable population (defined as individuals with mental&#xD;
             disability, persons in nursing homes, impoverished persons, homeless persons, nomads,&#xD;
             refugees and those permanently incapable of giving informed consent; vulnerable&#xD;
             populations also may include members of a group with a hierarchical structure such as&#xD;
             university students, subordinate hospital and laboratory personnel, employees of the&#xD;
             Sponsor, members of the armed forces and persons kept in detention)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Charles (Chuck) Simonton, MD FACC FSCAI</last_name>
    <phone>978-646-1597</phone>
    <email>csimonton@abiomed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adam Thompson</last_name>
    <phone>208-271-1610</phone>
    <email>adthompson@abiomed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mustafa Ahmed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abrazo Arizona Heart</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Medical Center - Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hursh Naik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tucson Medical Center HealthCare</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Thomas Waggoner, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Cardiology</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ernesto Ruiz-Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adventist Health Glendale</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hambik Tankazyan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Suhail Dohad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital - Orange</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Brian Kolski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Health</name>
      <address>
        <city>San Bernardino</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Aditya Bharadwaj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ehtisham Mahmud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Torrance Memorial Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michael Wyman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hayder Hashim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cardiac &amp; Vascular Institute</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Matheen Khuddus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida Health - Gainesville</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>R. David Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William Nicholson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Cardiovascular Institute</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michele Voeltz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wellstar Kennestone Hospital</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Salvatore Mannino, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthShore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Ricciardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Keith Benzuly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Christ Medical Center</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Thomas Levin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South (Lafayette General Medical Center)</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70596</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Louis Salvaggio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Foundation Hospital</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rajan Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Navin Kapur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Rahul Sakhuja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Robert Yeh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mir B. Basir, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension St. John Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Amir Kaki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Wohns, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metropolitan Heart and Vascular Institute / Metropolitan Cardiology Consultants</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jeffrey Chambers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CentraCare (St. Cloud Hospital)</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thom Dahle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Adam Salisbury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catholic Medical Center</name>
      <address>
        <city>Manchester</city>
        <state>New Hampshire</state>
        <zip>03102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stephan Heo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Haroon Faraz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lovelace/New Mexico Heart Institute</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Raymond Yau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - Moses</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467-2401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dimitrios Bliagos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Craig Thompson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mt. Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Samin Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Cenrer/NYPH</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Collins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Hospital (SUNY)</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Robert Pyo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Peter M Belford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linder Research Center (The Christ Hospital)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Timothy Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jaikirshan Khatri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence St. Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jason Wollmuth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mithun Chakravarthy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wellmont Cardiology Services</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>D. Christopher Metzger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centennial Heart - Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andrew Goodman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension St. Thomas West</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Elias Haddad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Colin Barker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presbyterian Hospital Dallas / Texas Health Physicians Group</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical City Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Amir Malik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCA Houston Healthcare</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pranav Loyalka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Heart Institute at Baylor St. Luke's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Samar Sheth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Heart - Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sameh Sayfo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk Health System</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthew Summers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VCU Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lorenzo Azzalini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kathleen Kearney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-ST Elevated Myocardial Infarction</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Heart Diseases</keyword>
  <keyword>Myocardial Ischemia</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Anterior Wall Myocardial Infarction</keyword>
  <keyword>Inferior Wall Myocardial Infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

